Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

Acute myeloid leukemia (AML) treatment is challenging in older patients. There is a lack of
evidence-based recommendations for older patients≥ 70, a group largely …

Simple Summary The combination of venetoclax and azacititine (VEN–AZA) has recently
been approved for the treatment of unfit newly diagnosed (ND) acute myeloid leukemia …

Background The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML)
leads to no response to venetoclax (VEN)–based therapy in more than half of the patients …

Background Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in
elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in …

Simple Summary Venetoclax (VEN) is a potent oral inhibitor of the anti-apoptotic molecule
BCL2, approved for adults with chronic lymphocytic leukemia (CLL), and recently for naïve …

Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) is hallmarked by dramatic
prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell …

Patients with acute myeloid leukemia (AML) refractory to intensive induction therapy
(primary induction failure) have an unfavorable outcome. In elderly patients not fit for further …

Venetoclax, an oral BCL‐2 inhibitor, has been widely incorporated in the treatment of acute
myeloid leukaemia. The combination of hypomethylating agents and venetoclax is the …